NewAmsterdam Pharma Inducement Share Options Overview
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) is making significant strides in expanding its leadership team. Recently, the company announced the approval of inducement share options for new executives, marking an exciting phase in its growth. This strategic move focuses on attracting top talent to advance its mission of improving patient care for those at risk of cardiovascular disease, particularly among those with elevated low-density lipoprotein cholesterol (LDL-C).
Details of the Inducement Grants
The Compensation Committee of NewAmsterdam's Board of Directors has approved the granting of share options totaling 58,000 ordinary shares. This allocation includes options for two non-executive new hires. In addition to this, the company granted 170,800 shares to its newly appointed Chief People Officer, Maryellen McQuade. This move is designed to facilitate her acceptance of a key leadership role within NewAmsterdam.
Vesting Schedule and Terms
The share options come with an exercise price set at $25.94, reflecting the closing price of NewAmsterdam’s stock on January 3, 2025. The shares granted will follow a structured vesting schedule that spans four years. Initially, 25% of the shares will vest on the one-year anniversary of the vesting commencement date. Following that, the remaining shares will vest in 36 equal monthly increments, contingent upon the employee’s ongoing service with NewAmsterdam.
Restricted Stock Units for New Chief People Officer
Alongside share options, Ms. McQuade also received a significant grant of restricted stock units totaling 36,600 ordinary shares. These units aim to incentivize her as she undertakes her role with NewAmsterdam. The restricted units were awarded on January 7, 2025, and will vest over three years. Specifically, one-third of the units will vest on each anniversary of the award, contingent on her continued service to the company.
The Importance of Attracting Talent
Recruiting exceptional talent like Ms. McQuade is a strategic priority for NewAmsterdam. The company understands that proficient leadership is crucial to navigate the complexities of the biopharmaceutical landscape effectively. By offering these inducement options, NewAmsterdam demonstrates its commitment to building a robust team to develop therapies that address unmet needs in metabolic diseases.
About NewAmsterdam Pharma Company
NewAmsterdam Pharma (NASDAQ: NAMS) is dedicated to improving patient outcomes in populations suffering from metabolic diseases. The company is particularly focused on providing a safe, tolerable, and efficient LDL-lowering therapy for patients inadequately served by current options. One of the primary projects includes obicetrapib, a once-daily CETP inhibitor. NewAmsterdam is conducting extensive phase 3 studies to determine the effectiveness of obicetrapib, both independently and in combination with ezetimibe, as a treatment adjunct to statins for patients at heightened risk of cardiovascular diseases.
Company Contact Information
For further inquiries, Matthew Philippe is the primary contact for NewAmsterdam. You can reach him at 1-917-882-7512. For additional information or to discuss matters further, his email address is matthew.philippe@newamsterdampharma.com.
Frequently Asked Questions
What are the inducement grants given to NewAmsterdam's new hires?
The inducement grants consist of share options and restricted stock units aimed at attracting and retaining key executives.
What is the primary purpose of these inducement options?
The options are designed to encourage top talents to join NewAmsterdam and commit to its vision of addressing cardiovascular disease.
How are the share options structured?
The share options have a four-year vesting schedule with a specific exercise price set at $25.94.
Who are the recipients of the inducement grants?
The grants were awarded to new executives, including Chief People Officer Maryellen McQuade.
What is NewAmsterdam's mission?
NewAmsterdam Pharma aims to provide effective LDL-lowering therapies and improve care for patients at risk of cardiovascular disease.
